Voluntary announcement - ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline for the treatment of obesity
Filed with HKEX · Stock code 1672 ·
6ix is reading this filing.
View original source (HKEXnews)Ascletis Pharma, Inc. on 6ix
Earlier from Ascletis Pharma
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
- Interim Report 2026
- Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
Later from Ascletis Pharma
All Ascletis Pharma news releasesFollow Ascletis Pharma into a list and get an email when it puts out news.
Follow Ascletis Pharma